Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The Opportunity:
We are seeking a passionate and energetic individual with strong PKPD modeling background to be part of the Nonclinical Development and Clinical Pharmacology (NDCP) Organization. As a PKPD modeler to support the pharmacometrics functions in the department, you will:
-
Establish population PK models to identify intrinsic and extrinsic factors that impact PK, and to guide dose/schedule optimization and recommended phase 2 dose/schedule (RP2Ds) selection.
-
Perform model-based simulations to optimize dosing to inform trial designs and clinical outcomes. Ensure quality and integrity of modeling and simulation results.
-
Author and provide technical input for regulatory documents and submissions related to all aspects of pharmacometrics (including protocol, IB, briefing package, etc) and responses to regulatory questions.
-
Engage and work with consultants and/or CROs on pharmacometrics activities to complement in-house knowledge/expertise and capacities.
Required Skills, Experience, and Education:
-
A Ph.D. or Pharm.D. with 5+ years of experience in PKPD Modeling & Simulation.
-
Extensive hands-on experience using NONMEM modeling software is a must.
-
Familiar with common PKPD/TGI models and able to write customized NONMEM models.
-
At least two years of relevant work experience in pharmaceutical companies.
-
Proficiency in R programming is desired.
-
Able to take dynamically assigned pharmacometrics tasks and deliver the results in a timely manner.
-
Excellent verbal and written communication skills, and ability to clearly convey complex concepts and findings to both non-specialist and specialist audiences.
-
A critical thinker and passionate team player and quick learner with high energy who thrives in a dynamic and fast-paced environment.
-
Demonstrated experience and track record in clinical-stage drug development is a big plus but not required.
Preferred Skills:
-
Have prior knowledge or familiarity with longitudinal model analysis (e.g. ctDNA and tumor shrinkage).
-
Have prior knowledge or familiarity with ER analysis for oncology compounds
-
Familiar with data handling.
The base salary range for this full-time position is $175,000 to $210,000 for candidates based at our headquarters in Redwood City, CA. The range displayed on each job posting is intended to be the minimum and maximum salary for the position in Redwood City and will be adjusted for the local market a candidate is based. Our salary ranges are determined by role, level, and location. Individual pay is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base salary is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact privacy@revmed.com.
#LI-Hybrid #LI-CT1